Risk factor
High price volatility
Profitability factor
Very strong margins and returns
About
This enterprise is dedicated to the investigation, advancement, and creation of pharmaceutical treatments leveraging human mesenchymal stem cells and immune cells. Its current portfolio features UMC01, a drug candidate undergoing Phase I clinical evaluation for addressing conditions such as myocardial infarction and stroke. Additionally, ADCV01 is progressing through Phase II clinical trials as a potential therapy for aggressive brain tumors. The company also develops CAR001, an innovative chimeric antigen receptor immune cell product, alongside bone-marrow stem cells (BMSC) used in managing chronic stroke, severe osteoarthritis, and spinal cord injuries. Established in 2016, the firm operates from its headquarters in Taichung, Taiwan.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'ex
Target Price
The average target price of 6712.TWO is 200 and suggests 40.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i